Nangali Srinivasa, MD
Nephrology · Pittsburgh, PANPI 1033137542
Payments from drug & device makers
Across 195 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$1K
- AstraZeneca$1K
- Lilly USA, LLC$465
- Vifor Pharma, Inc.$441
- Amgen$349
- Travere Therapeutics, Inc.$320
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$2003%
- Travel & lodging$68011%
- Food & beverage$4,85481%
- Education$2434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 10 | $1,347 |
| AstraZeneca(2 entities) | 46 | $1,036 |
| Lilly USA, LLC | 23 | $465 |
| Vifor Pharma, Inc. | 9 | $441 |
| Amgen | 15 | $349 |
| Travere Therapeutics, Inc. | 7 | $320 |
| Johnson & Johnson | 5 | $258 |
| Akebia Therapeutics Inc | 8 | $231 |
| Bayer | 6 | $152 |
| Mallinckrodt Hospital Products Inc. | 2 | $120 |
| Novo Nordisk | 6 | $110 |
| Corcept Therapeutics | 5 | $96 |
| Boehringer Ingelheim | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Fresenius USA Marketing, Inc. | 4 | $91 |
| Dexcom, Inc. | 4 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Shire North American Group Inc | 4 | $69 |
| BD | 4 | $64 |
| Ardelyx, Inc. | 2 | $64 |
| Novartis | 2 | $53 |
| Merck | 3 | $50 |
| Insulet Corporation | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Nxstage Medical, Inc. | 1 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $22 |
| Medtronic | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,977 in reported general payments places this provider in the 80th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $62,744 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $18,396 |
| ProsolParenteral Amino Acid 20% No.1 | 49 | $11,481 |
| Sevelamer Carbonate | 56 | $9,294 |
| EliquisApixaban | 18 | $7,559 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $6,928 |
| Calcium Acetate | 99 | $5,494 |
| Potassium Citrate ErPotassium Citrate | 19 | $4,403 |
| UloricFebuxostat | 12 | $3,796 |
| Midodrine Hcl | 29 | $2,146 |
| Nifedipine ErNifedipine | 94 | $1,787 |
| Bumetanide | 42 | $1,243 |
| Cinacalcet Hcl | 12 | $830 |
| Hydralazine Hcl | 39 | $663 |
| Losartan Potassium | 52 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $96 | $62,74458 claims |
| AstraZenecaLokelma | $1,036 | $6,92813 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $19 | $13813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Pittsburgh
- Christopher GislerPittsburgh$757K
- Swati AroraPittsburgh$388K
- Kelly LiangPittsburgh$208K
- Khaled NasharPittsburgh$198K
- Linda FriedPittsburgh$112K
- Mohan RamkumarPittsburgh$53K
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Nelson KopytAllentown$2.1M
- Iris LeePhiladelphia$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.